Trial Profile
A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel Group Study of the Efficacy and Safety of Intraprostatic Administration of BOTOX® 200 U (Botulinum Toxin Type A) Purified Neurotoxin Complex to Treat Lower Urinary Tract Symptoms due to Benign Prostatic Hyperplasia
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Oct 2021
Price :
$35
*
At a glance
- Drugs Botulinum-Toxin-A (Primary)
- Indications Lower urinary tract symptoms
- Focus Therapeutic Use
- Sponsors Allergan
- 06 Feb 2014 Results published in the Journal of Urology.
- 11 Sep 2013 Planned number of patients changed from 274 to 315 as reported by German Clinical Trials Register record.
- 29 Aug 2012 New source identified and integrated (German Clinical Trials Register; DRKS00004074).